Indeed, the S1PR1/3 antagonist, VPC23019, significantly inhibited S1P-induced OSCC cell migration (Figure S6), consistent with other reports in different tumour types36, 37, 38, 39, 40. Here, S1PR1 is linked to neoplasm.